Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home

Accessibility

Text size:

This site uses the Open Source Content Management System Plone and has been designed to be completely accessible and usable, working in accordance with the Web Content Accessibility Guidelines (WCAG v1.0). If there is anything on this site — accessibility or validation related — that is not according to the standard, please contact the Site Administration, and not the Plone Team.

Access keys

Access keys are a navigation device enabling you to get around this web site using your keyboard.

Available access keys

This site uses a setup that closely matches most international recommendations on access keys. These are:

  • 1 — Home Page
  • 2 — Skip to content
  • 3 — Site Map
  • 4 — Search field focus
  • 5 — Advanced Search
  • 6 — Site navigation tree
  • 9 — Contact information
  • 0 — Access Key details

Accessibility Statement

We have undertaken to use our knowledge and understanding of the ways in which different people access the Internet, to develop a web site that is clear and simple for everybody to use.

Validation

We have used XHTML 1.0 and CSS that conforms to specification, as laid out by the W3C because we believe that usability and accessibility must have a solid foundation. If anything on this web site does not validate correctly, please contact the Site Administration, and not the Plone Team.

We have also endeavoured to achieve AA accessibility as measured against version 1.0 of the WCAG. We are aware however, that a number of the checkpoints of the WCAG are subjective — and although we are sure that we have met them squarely, there may be instances where interpretation may vary.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.